Literature DB >> 33403572

Evaluation of patient attitudes towards the technical experience of synchronous teledermatology in the era of COVID-19.

Ross L Pearlman1, Phuong B Le1, Robert T Brodell1, Vinayak K Nahar2,3.   

Abstract

Teledermatology has become critical for maintaining patient access to dermatologic services since the eruption of the COVID-19 pandemic. This survey of first-time synchronous teledermatology patients (n = 100) seen by providers of the University of Mississippi Medical Center during Spring 2020 was designed to learn more about patient experiences associated with the technical challenges of synchronous teledermatology. Our patient population had considerable experience with various social media including Facebook (82%) and hardware platforms, such as Apple devices (66%). We found that the majority of patients were satisfied (88.9%) with their synchronous teledermatology encounter and 81.8% of patients did not experience a technical difficulty with their consult. About 15% of patients lost connection with their provider during their consultation. Furthermore, about 30% of patients rated "showing their skin" to their provider as "hardest" on a ten scale. However, about 34% of patients sent "store-and-forward"-type images to supplement their encounter. Despite overwhelming satisfaction with synchronous teledermatology, a majority prefer an in-person consultation for their next visit (68.7%). Synchronous teledermatology offers a critical service to patients to expand access to specialty consultation. It is well-received by patients despite technical barriers, especially during a global health crisis.

Entities:  

Keywords:  Attitudes; COVID-19; Experience; Teledermatology; Telehealth

Year:  2021        PMID: 33403572     DOI: 10.1007/s00403-020-02170-2

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  7 in total

Review 1.  Teledermatology During COVID-19: An Updated Review.

Authors:  Morgan A Farr; Madeleine Duvic; Tejas P Joshi
Journal:  Am J Clin Dermatol       Date:  2021-04-09       Impact factor: 6.233

2.  Factors influencing use and perceptions of teledermatology: A mixed-methods study of 942 participants.

Authors:  Ellie Ci-En Choi; Li Wei Heng; Sean Yilong Tan; Phillip Phan; Nisha Suyien Chandran
Journal:  JAAD Int       Date:  2022-02-01

3.  Teledermatology to Facilitate Patient Care Transitions From Inpatient to Outpatient Dermatology: Mixed Methods Evaluation.

Authors:  Samantha M R Kling; Erika A Saliba-Gustafsson; Marcy Winget; Maria A Aleshin; Donn W Garvert; Alexis Amano; Cati G Brown-Johnson; Bernice Y Kwong; Ana Calugar; Ghida El-Banna; Jonathan G Shaw; Steven M Asch; Justin M Ko
Journal:  J Med Internet Res       Date:  2022-08-03       Impact factor: 7.076

4.  Assessment of dermatologists' perception of utilizing teledermatology during COVID-19 pandemic in Saudi Arabia.

Authors:  Hatoun M Almaziad; Abdulrahman I Alfawzan; Norah K Alkhayal; Rayan A Alkhodair
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

5.  A Multi-Site Survey Study of Patient Satisfaction with Teledermatology.

Authors:  Christy Nwankwo; Jessica E Houpe; Bao Vincent K Ho; Edward W Seger; Dominic J Wu; Anand Rajpara
Journal:  Kans J Med       Date:  2022-09-21

Review 6.  Teledermatology versus Face-to-Face Dermatology: An Analysis of Cost-Effectiveness from Eight Studies from Europe and the United States.

Authors:  Remedios López-Liria; María Ángeles Valverde-Martínez; Antonio López-Villegas; Rafael Jesús Bautista-Mesa; Francisco Antonio Vega-Ramírez; Salvador Peiró; Cesar Leal-Costa
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

Review 7.  Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications.

Authors:  Claudio Marasca; Maria Carmela Annunziata; Elisa Camela; Adriana Di Guida; Luigi Fornaro; Matteo Megna; Maddalena Napolitano; Cataldo Patruno; Luca Potestio; Gabriella Fabbrocini
Journal:  J Clin Med       Date:  2022-03-10       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.